Colorectal cancer is one of the leading causes of cancer death worldwide. Over the last decades, several studies have shown that tumor-related genomic alterations predict tumor prognosis, drug response, and toxicity. These observations have led to the development of several therapies based on individual genomic profiles. As part of these approaches, pharmacogenomics analyses genomic alterations which may predict an efficient therapeutic response. Studying these mutations as biomarkers for predicting drug response is of a great interest to improve precision medicine. We conduct a comprehensive review of the main pharmacogenomics biomarkers and genomic alterations affecting enzyme activity, transporter capacity, channels, and receptors; and therefore the new advances in CRC precision medicine to select the best therapeutic strategy in populations worldwide, with a focus on Latin America.
Introduction
Colorectal cancer (CRC) is one of the leading causes of cancer-related death worldwide [1] . In the last decade, numerous exciting advances have been made to treat patients even with metastatic CRC (mCRC) [2] . However, patient-tailored therapies are still needed to overcome this disease. The advance of precision medicine requires the accurate identification of mutations driving each patient's tumor [3] . In this regard, genetic mutations may have a great impact on disease prognosis and therapy response. Germline mutations are heritable alterations found in individuals while somatic mutations appear after an oncogenic * Andrés López-Cortés aalc84@gmail.com * César Paz-y-Miño cesar.pazymino@ute.edu.ec
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insult within the tumoral tissue [4] . As part of CRC pharmacogenomics, precision medicine allows tailoring drug development based on the human multi-omics profile [5] [6] [7] . Thus, personalized therapy not only maximizes the drug therapeutic effects but also reduces the possibility of experiencing adverse drug reactions [8] . In this review, we focus primarily on the current status of pharmacogenomics in CRC, its biomarkers and allele frequencies worldwide, with a focus on Latin American populations in order to improve precision medicine.
Platinum derivatives
These compounds form covalent bonds with guanine and adenine in the DNA. The most important drugs in this group are cisplatin, carboplatin, and oxaliplatin ( Fig. 2) . Drugs containing platinum salts exert their cytotoxic effect by means of DNA adduct formation, leading to inhibition of DNA replication and apoptosis [45] . The major path of adduct elimination is the nucleotide excision repair (NER). During NER, damaged DNA and unwound DNA helices are identified by the action of several factors, including xeroderma pigmentosum protein (XPD, XPC, and XPA) [46] . Cleavages of the damaged DNA strand are performed by nucleases XPG (3′) and ERCC1 (5′), and adducts are removed [47] . The glutathione S-transferases (GSTs) are involved in the inactivation of platinum compounds, thus preventing cellular DNA damage and increasing the treatment efficacy [48] . Single nucleotide polymorphisms (SNPs) in GSTP1, GSTT1, and GSTM1 can alter GST activity [49] . The Fig. 1 Integrating multi-omics features in CRC subtypes. Microsatellite instability (MSI) is linked to hypermutation, hypermethylation, highly immunogenic response, and locations in the proximal colon (consensus molecular subtype 1 (CMS1)). Tumors with chromosomal instability (CIN) are linked to copy number variations, poorly immunogenic or inflamed, non-hypermutated subtypes, stromal infiltration, and locations in left colon or rectum (CMS2, CMS3, and CMS4) For advanced or metastatic disease only decrease in enzyme activity has been linked to reduced detoxification capacity, leading to increased efficacy of platinum compounds. GSTP1 (Ile105Val) has been associated with reduced enzyme activity [50] , a deletion in GSTT1 leads to the absence of enzyme activity and a deletion in GSTM1 is linked with decreased survival rate [51, 52] . The excision repair cross-complementation protein (ERCC) is involved in nucleotide repair system [53] . Polymorphisms in genes encoding these repair proteins may contribute to inter-individual differences to platinum toxicity. The association between toxicity and ERCC1 rs11615 has been studied in CRC [54] . The mutant T allele has been related to grade 1 neuropathy in oxaliplatin-treated patients, even though no association with a higher degree of neuropathy was observed. Moreover, ERCC2 (XPD) is involved in the oxaliplatin pathway. rs13181 has been related with treatment effectiveness [55] . Meanwhile, ERCC4 rs1799801, ERCC5 rs2016073, and rs751402 are associated with platinum response [56] .
The X-ray repair cross-complementing protein (XRCC1) and its variant XRCC1 rs25487 are involved in the repair of broken DNA strands which can be induced by platinum compounds; such repair is carried out by an excision repair system [57] . It has been suggested that a deterioration in the efficiency of DNA repair caused by Gln's allele leads to greater efficacy of oxaliplatin. Conversely, the presence of XRCC3 rs1799794 has been associated with an increased risk of neutropenia [58] . Biomarkers focused on oxaliplatin are listed in Table 2 [49, [55] [56] [57] [59] [60] [61] [62] .
Pharmacogenomics identifies mutations, which may predict an efficient therapeutic response; however, genetic alterations significantly varies depending on different race/ ethnic origins worldwide [63] . The allele frequencies of Overview of different drugs used in the CRC treatments: a antiangiogenics, b drugs against EGFR, c antimetabolites, d platinum derivatives, e immune checkpoint inhibitors (anti PD-1, anti PD-L1, and TGFβ inhibitor), and f antitopoisomerase platinum derivative variants rs1695, rs11615, rs13181, rs1799801, rs2016073, rs2234671, rs25487, and rs1799794, according to the 1000 Genomes Project (phase 3) are shown in Table 3 [64].
Antimetabolites
These drugs inhibit enzymes related to purine and pyrimidine synthesis, resulting in cell depletion and alteration of nucleic acid synthesis. Among these, there are pyrimidine analogs such as 5-fluorouracil (5-FU) and oral pro-drugs such as gemcitabine, capecitabine and tegafur ( Fig. 2) [65] .
Fluoropyrimidines (5-FU, capecitabine and tegafur) are antimetabolite drugs used in CRC treatment. 5-FU is a fluoropyrimidine derivative with two major mechanisms of action that explain its cytotoxic effect [66] . The main active metabolite of 5-FU (5-FdUMP) prevents DNA synthesis by forming a complex with thymidylate synthase (TS) stabilized by 5,10-methylenetetrahydrofolate (5,10-MTHF), thus inhibiting the conversion of monophosphate 2′-deoxyuridine-5′ (dUMP) to deoxythymidine-2′-5′-monophosphate (dTMP), an essential precursor for DNA synthesis. In addition, the incorporation of 5-FU to nucleotides in DNA and RNA strands leads to an alteration in the processing of nucleic acids [66] . Gemcitabine is a structural analog of deoxycytidine, which is metabolized by nucleoside kinase to nucleoside diphosphate and triphosphate [67] .
TYMS protein is a homodimeric methyltransferase enzyme that catalyzes the synthesis reaction of thymidylate. This reaction is a critical step in the formation of deoxythymidine 5′-triphosphate (dTTP), an indispensable metabolite in DNA synthesis. The TYMS gene contains a tandem of a polymorphic 28-base-pair sequence repeated in the promoter (TSER) 5′ untranslated region (5′-UTR) [67] .
Inactivation of 5-FU depends on dihydropyrimidine dehydrogenase (DPYD) activity [68] . The deficient activity of DPYD leads to prolonged 5-FU plasma half-life, causing a severe hematological toxicity [69] . DPYD deficiency is present in~3% of all cancer patients, but it represents approximately 50% of patients manifesting severe toxicity. So far,~30 polymorphisms in DYPD have been identified; however, a mutation of G>A at the splicing site in exon 14 (IVS14 + 1G>A) leads to the formation of a truncated protein without residual activity [70, 71] . The incidence of this allele is rare, with a heterozygote population frequency of 0.9-1.8%. Nevertheless, it is estimated to be responsible for approximately 25% of all cases of 5-FU unexpected toxicity [66] .
Methylenetetrahydrofolate reductase (MTHFR) catalyzes the conversion of 5,10-MTHF to 5-MTHF. The most common polymorphisms of MTHFR are C677T and A1298C. These polymorphisms lead to decreased enzyme activity, which induces a more effective stabilization of the FdUMP-TS ternary complex, potentiating 5-FU toxicity [72, 73] .
ATP-Binding Cassette Sub-Family B1 (ABCB1) is a member of the ABC transporter superfamily and its protein is known as P-glycoprotein [74] . ABCB1 overexpression in tumors has been associated with resistance to chemotherapeutic drugs. ABCB1 is a highly polymorphic gene that significantly differs among ethnic groups. Some of the most studied SNPs are rs1128503, rs2032592, and rs1045642 [75] .
Cytidine deaminase (CDA) is involved in capecitabine metabolism in the liver to form 5-fluorodeoxyuridine, which in turn becomes 5-FU by the action of thymidine phosphorylase (TP) [67] . The decreased activity of CDA leads to the accumulation of potentially toxic metabolites. The variation in expression of CDA has been linked to polymorphisms in the promoter region of CDA and affects the GSTP1 glutathione S-transferase pi 1, GSTM1 glutathione S-transferase mu 1, ERCC1 excision repair 1, ERCC2 excision repair 2, ERCC4 excision repair 4, ERCC5 excision repair 5, XRCC1 X-ray repair cross complementing 1, XRCC3 X-ray repair cross complementing 3, del deletion, G guanine, A adenine, C cytosine, T thymine metabolism of gemcitabine and capecitabine [74] . rs602950 and rs532545 have been associated with increased expression of CDA in vitro in capecitabine-treated patients [74] . TP is involved in 5-FU metabolism, where 5-FU is converted to 5-fluoro-2′-deoxyuridine (FUDR-5) [76] . rs11479 generates an amino acid change of serine to leucine that leads to a lower treatment response. Enolase superfamily member 1 (ENOSF1) gene encodes an antisense RNA against TYMS. ENOSF1 regulates mRNA and protein expression of TYMS. Hence, TYMS variants with lower or higher activity affect its function [70, 71] . Lastly, biomarkers focused on capecitabine, 5-FU and gemcitabine drugs are listed in Table 4 [70, 71, [74] [75] [76] [77] [78] [79] [80] .
The allele frequencies of rs3918290, rs1801133, rs1128503, rs2072671, rs9344, rs9344, and rs2612091 polymorphisms in populations worldwide are shown in Table 5 [64].
Agents interacting with topoisomerases
Topoisomerases play a key role in the cell replication, transcription, and DNA repair. It modifies the tertiary DNA structure without altering the nucleotide sequence. In humans, three types of topoisomerases (I, II, and III) have been identified. Within this group, camptothecin derivatives such as irinotecan are included [81] (Fig. 2) .
Irinotecan is a potent inhibitor of topoisomerase I [82] . It promotes an oxidation bioreaction mediated by CYP3A to form APC, a cytotoxic substance. Alternatively, irinotecan is converted by hepatic carboxylesterase to SN-38. This compound is conjugated further by several UDP glucuronyl to reach the inactive metabolite SN-38G [83] . To enable excretion, SN-38 and irinotecan are actively transported out of the cell by ATP-dependent efflux pump (ABCB1). After biliary excretion, SN-38G can become active SN-38 by It has been revealed that reduced glucuronidation of SN-38 significantly increases irinotecan gastrointestinal toxicity. The main UDP-glucuronosyltransferase (UGT) involved in conjugating SN-38 is UGT1A1. At least 25 UGT1A1 polymorphisms have been described, from which the most common in the promoter region consists of seven TA-repetitions (−53 [TA] 6 > 7, UGT1A1*28) instead of six [84, 85] . The highest number of TA repeats is associated with a reduction of UGT1A1 expression, leading to reduced glucuronidation. UGT1A1*28 has proven to be a significant predictor of severe toxicity following administration of irinotecan [86, 87] .
ABC transporters, including ABCC1, ABCC2, ABCB1, and ABCG2 regulate output of hepatic and biliary CPT-11 metabolites [88] . SNPs in ABCB1 and ABCC2 have been recently associated with modulation of CPT-11 and SN-38 exposure [82] . Moreover, other SNPs in ABCC5 and ABCG2 genes have been correlated with both hematological and nonhematological toxicities [89] .
The solute carrier organic anion transporter family member 1B1 (SLCO1B1) is an important prptein expressed in the basolateral membrane of hepatocytes, which mediates the availability of active irinotecan metabolite [90] . rs4149056 has been associated with an increased SN-38 concentration in patients with mCRC. Meanwhile, other polymorphisms are linked to faster response rate and higher PFS [83] . Finally, biomarkers focused on irinotecan drug are shown in Table 6 [52, 59, 62, 74, 75, 84, 85, 87, [89] [90] [91] [92] [93] [94] [95] .
The allele frequencies of genes that interact with topoisomerases rs2244613, rs1045642, rs2074087, rs262604, rs1051266, and rs2306283 in populations worldwide are shown in Table 7 [64].
Antiangiogenics
Vascular endothelial growth factor (VEGF) is a major regulator of angiogenesis and inhibition mediated by bevacizumab which reduces tumor volume [96, 97] . Bevacizumab is a recombinant humanized monoclonal IgG antibody directed against all isoforms of VEGFA. Hypoxia is a potent stimulus for VEGF expression and one of the control elements in this mechanism is the hypoxia-inducible factor 1A (HIF-1a) [98] . This factor binds to a 28-bp promoter in the 5′ upstream region of VEGF, thereby/hencestimulating transcription. In addition, other regulatory elements for VEGF expression are found in the 3′-UTR as shown in Table 8 [98] [99] [100] [101] . Variations in the VEGF receptor 1 (rs9582036) and 2 (rs12505758) are associated with tyrosine kinase (TKI) domain. High expression levels of these receptors contribute to a less favorable outcome when treated with bevacizumab, linked with PFS and overall survival (OS) [96, 100, 102] .
Various studies from mCRC have investigated the predictive impact of some SNPs present in VEGFA, which are involved in bevacizumab response. Loupakis et al. conducted a retrospective analysis which found that rs833061 was associated with PFS and OS [100] . Meanwhile, Sibertin-Blanc et al. [103] showed that T-carriers of the C237T SNP had shorter time-to-treatment failure as well as shorter PFS and OS.
Annexin A11 (ANXA11) has been associated with a spectrum of regulatory functions in calcium signaling, cell division, and apoptosis [104] . ANXA11 rs1049550 leads to an amino acid change (R230C) of the first conserved domain of annexin, which is responsible for Ca +2 dependent intracellular traffic. Response to bevacizumab revealed that patients carrying rs1049550 were more sensitive to chemotherapy than those having at least one C allele [101] .
CXC chemokine receptors (CXCR1 and CXCR2) are integral membrane proteins which specifically bind and respond to CXC chemokine family cytokines [99] . They represent a family of seven receptors linked to G-protein which plays an important role in angiogenesis. CXCR1 rs2234671 and CXCR2 rs2230054 are linked with overall response rates (ORR) [105] .
Finally, the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved new molecules that improve the therapeutic effectiveness, OS, and PFS. In particular, research efforts have been focused on novel agents targeting tumor angiogenic activity, cell growth, and migration in mCRC. The use of molecules targeting VEGF pathways (ziv-aflibercept, regorafenib and ramucirumab) have been integrated into clinical practice [96] (Fig. 2) .
The allele frequencies of variants that interact with antiangiogenic agents rs9582036, rs12505758, rs3025039, rs1049550, and rs2230054 in populations worldwide are shown in Table 9 [64].
Agents against EGFR
Cetuximab and panitumumab are monoclonal antibodies (mAb) that block the action of EGF and may be employed in mCRC treatment [9, 98] . These drugs exert their action by binding to the extracellular domain of EGFR, with a greater affinity compared with the wild-type EGF, thereby blocking phosphorylation induced by EGFR ligands. Some variants are shown in Table 10 [69, 70, 80, 107-113-114] .
The EGF/EGFR pathway plays an important role in cancer pathogenesis. EGF and EGFR are commonly overexpressed in CRC and they appear to be associated with poor prognosis and increased metastatic risk [115] . EGFR is a transmembrane glycoprotein which is involved in cell proliferation, migration, and survival. EGFR R497K attenuates TKI activation [116] , and EGF G61A increases its production when individuals have GG or GA genotypes [111] . The EGF/EGFR pathway is a predictive marker for cetuximab treatment in patients with locally advanced CRC [117] .
KRAS oncogene is a member of the human RAS family, which produces a self-inactivating guanosine triphosphate (GTP), binding signal transducer located on the inner surface of the cell membrane [118] . KRAS mutations may compromise the intrinsic GTPase activity, resulting in constitutively active KRAS protein that affects various signaling pathways [118] . The 45% of CRC cases have KRAS mutations and it has been shown that these mutations are predictive biomarkers of poor outcome in mCRC treated with cetuximab [119] . The anti-EGFR mAb therapy significantly improves both PFS and OS tumors without mutations in RAS. Therefore, mutations in KRAS predict resistance to mAb directed to EGFR with cetuximab and panitumumab [106] . NRAS codifies an isoform of RAS protein, involved primarily in the regulation of cell division [114] . Mutations in exon 2, 3, and 4 of NRAS, in addition to those in exon 2 of KRAS, must be detected before administration of a monoclonal anti-EGFR [106] . According to the NCCN, KRAS and NRAS are the only one predictive biomarkers approved in mCRC. Cetuximab and panitumumab are applied on patients with nonmutated RAS whereas bevacizumab is applied on patients with mutated RAS [11] .
Regarding Fc receptor range, modulating the immune response could be a further important mechanism to cetuximab sensitivity. The immune mechanism of antibodydependent cell-mediated cytotoxicity (ADCC) through Fc receptors (Fc gamma R) made by immune cells, plays a main role in the effect of IgG1 antitumor antibodies [120, 121] . The most common polymorphisms in FCGR2A and FCGR3A are rs1801274 and rs396991, respectively [122, 123] . ABCB1 ATP binding cassette subfamily B member 1, ABCC1 ATP binding cassette subfamily C member 1, ABCC2 ATP binding cassette subfamily C member 2, ABCG2 ATP binding cassette subfamily G member 2, PFS progression-free survival, CYP3A5 cytochrome P450 family 3 subfamily A member 5, UGT1A1, UDPglucuronosyltransferase family 1 member A1, UGT1A7 UDP glucuronosyltransferase family 1 member A7, UGT1A9 UDP glucuronosyltransferase family 1 member A9, SLC19A1 solute carrier family 19 member 1, SLCO1B1 solute carrier organic anion transporter family member 1B1, G guanine, A adenine, C cytosine, T thymine, * repetitions It is known that cetuximab is a standard-of-care treatment for RAS wild-type mCRC but not for those harboring KRAS mutations since MAPK pathway is constitutively activated. Nevertheless, cetuximab also exerts its effect by its immunomodulatory activity despite the presence of RAS mutations [124] . According to Borrero-Palacios et al., cetuximab has the potential therapeutic in KRAS mutated mCRC carrying nonfunctional receptor KIR2DS4 and FCGR2A H131R polymorphism since these patients significantly prolonged their OS. Moreover, these results explain the variable efficacy of cetuximab in mCRC patients with KRAS mutations and confirm the role of ADCC-mediated toxicity to tumor cells by cetuximab [124] .
The phosphatidylinositol 3-kinase (PI3K/AKT) pathway is involved in cancer pathogenesis, being imperative the design of therapeutic inhibitors [125] . PIK3CA gene encodes the p110 catalytic subunit of PI3K alpha. PIK3CA mutations (associated with KRAS mutation and MSI) stimulate AKT pathway and promote cell growth in CRC [125] . PIK3CA mutations in exon 9 and 20 affects the helical and kinase domains of the protein, promoting a lack of effectiveness in drug treatments [112] .
BRAF protein is part of the RAS/MAPK signaling pathway, which regulates cell growth, proliferation, migration, and apoptosis [126] . BRAF is a driver gene whose mutations are inversely associated with treatment response and are mutually exclusive with RAS mutations [114, 127] . Hence, BRAF V600E mutation correlates with worse prognosis [128] . Vemurafenib is a third-line therapeutic option in advanced mCRC with BRAF mutations [129] . Furthermore, it has been proposed that patients with KRAS and BRAF mutations could be eligible for mAb treatment against EGFR. Finally, BRAF must not present any mutation for a favorable treatment response when panitumumab or cetuximab are applied [113] . COX is the limiting enzyme in the conversion of arachidonic acid into prostaglandins. COX2, encoded by prostaglandin endoperoxide synthase 2 (PTGS2), is involved in metastasis and chemotherapy resistance [130] . ANXA11 annexin A11; CXCR2, C-X-C motif chemokine receptor 2, VEGFA vascular endothelial growth factor A, VEGFR1 vascular endothelial growth factor receptor 1, VEGFR2 vascular endothelial growth factor receptor 2, G guanine, A adenine, C cytosine, T thymine a Frequency of minor allele ANXA11 annexin A11, CXCR1 C-X-C motif chemokine receptor 1, CXCR2 C-X-C motif chemokine receptor 2, VEGFA, vascular endothelial growth factor A, VEGFR1 vascular endothelial growth factor receptor 1, VEGFR2 vascular endothelial growth factor receptor 2, G guanine, A adenine, C cytosine, T thymine, OS overall survival, PFS patient-free survival, ORR overall response rates High levels of COX2 are linked with shorter OS in CRC. The C allele of COX2 G765C polymorphism has been associated with a significantly lower promoter activity [110, 131] . The allele frequencies of rs2227983, rs4444903, rs1801274, rs396991, and rs20417 genetic variants in populations worldwide are shown in Table 11 [64].
CRC immunogenomics
Recent advances in cancer immunology have highlighted the immunogenic nature of CRC and provided insights regarding the complex tumor-immune system interactions that drive immune evasion in CRC [132] [133] [134] . One of the mechanisms that mediates tumor-associated immune escape is the activation of inhibitory co-receptors or immune checkpoints on the T lymphocyte surface by tumor cells through the expression of immunosuppressive molecules [132, 133, 135] .
Programmed cell death protein 1 (PD-1, CD279) is an inhibitory co-receptor expressed by exhausted tumorinfiltrating lymphocytes (TILs) present within the tumor microenvironment [135] [136] [137] . PD-1 engages with programmed-death ligands 1 (PD-L1, BT-H1, CD274) and 2 (PD-L2, B7-DC, CD273) which are expressed by CRC cells [138] [139] [140] [141] . PD-1/PD-L1 interaction inhibits CD8 + T-cell activation, cytokine production, proliferation, and cytotoxicity which suppresses the host immune response and allows CRC cells to proliferate and metastasize [135] [136] [137] .
Immune checkpoint inhibition has revolutionized cancer immunotherapy since it has proven to be very successful for treatment of melanoma and nonsmall cell lung cancer [143] [144] . It has been shown that PD-1 blockade is a highly efficient therapeutic strategy against MSI-high and MMRd CRC tumors since these tumors display dense lymphocyte infiltrates due to their increased expression of immunogenic neo-antigens [145] [146] [147] . Moreover, these tumors exhibit higher PD-1 expression on TILs and PD-L1 expression than microsatellite stable tumors [147, 148] . Subsequently, the FDA approved pembrolizumab and nivolumab, two anti PD-1 antibodies, for treatment of metastatic MSI-high or MMRd solid tumors.
According to Tauriello et al., inhibition of the PD-1 and PD-L1 immune checkpoints provoked a limited response in quadruple-mutant mice [149] . By contrast, his results strongly suggest that inhibition of TGFβ signaling could be promising as immunotherapy for patients with microsatellite stability and stroma-rich CRCs, enduring cytotoxic T-cell response against tumor cells that prevent metastasis [149] [150] [151] . The clinical implications of CRC immunogenomics continue to expand, and it will likely serve as a guide for next-generation immunotherapy strategies for improving outcomes for this disease (Fig. 2) . The Pan-Cancer Atlas: germline pathogenic variants
The Pan-Cancer Atlas provides a panoramic view of the oncogenic processes that contribute to human cancer. It reveals how genetic variants collaborate in cancer progression and explores the influence of mutations on cell signaling and immune cell composition, providing insight to prioritize the development of new immunotherapies [152] . According to Huang et al., the Pan-Cancer Atlas analyzed 564 CRC samples and found several pathogenic germline variants in the APC, ATM, ATR, BARD1, BLM, BRCA1, BRCA2, BRIP1, CHEK2, COL7A1, FANCI, GJB2, MLH1, MSH2, MSH6, PALB2, POT1, RAD51D, RECQL4, RET, RHBDF2, and SDHA genes [153] . In addition, Table 12 shows the allele frequencies of those 29 pathogenic germline variants according to The Exome Aggregation Consortium (ExAC) [154] .
Clinical trials for metastatic CRC Figure 3 shows the current status of clinical trials for mCRC according to the Open Targets Platform [155] . There are 79 The greatest number of clinical trials was in phase 2 (60%). Small molecules were the most analyzed type of drug (77%), followed by antibodies (20%) and proteins (3%). Lastly, the target classes with the greatest number of clinical trials were transferases (13%), followed by TKIs of EGFR family (10%) and isomerases (10%). However, all TKIs made up the 41% of target classes [155] ( Supplementary  Table 2 ). Figure 4 shows the proposed biomarker network in CRC. The protein-protein interaction (PPi) network with a highest confidence cutoff of 0.9 was created using String Database [156] . This network is made up of known and predicted interactions of driver genes [157] , nodes with pathogenic germline and somatic mutations according to the Pan-Cancer Atlas [39, 153] and the CGI [41] , respectively, and druggable enzymes according to the Pharmacogenomics Knowledge Base (PharmGKB) [158, 159] . The enrichment analysis of gene ontology terms related to biological processes and metabolic pathways were carried in the 87 genes of CRC biomarker network (Fig. 4) . The top biological processes with significant false discovery rate (FDR) < 0.01 were DNA synthesis involved in DNA repair, strand displacement and response to drug. Meanwhile, the top metabolic pathways with FDR < 0.01 were colorectal, endometrial, and pancreatic cancer types [160] .
Biomarker network in CRC

Pharmacogenomics in clinical practice
In addition to the NCCN and ESMO guidelines [42] [43] [44] , the Canadian Pharmacogenomics Network for Drug Safety, the Royal Dutch Association for the Advancement of Pharmacy, and the Clinical Pharmacogenetics Implementation Consortium have published precise guidelines for the application of pharmacogenomics in clinical practice [161] [162] [163] . All this information is published in the PharmGKB, which is a comprehensive resource that curates knowledge Table 3 ).
Additionally to the 1000 Genomes Project (Phase 3) [64], we included 33 studies that have published the allele frequencies of mutations in several druggable enzymes in 34 different ethnic populations from Latin America ( Supplementary Tables 4-11 ). Human populations from this geographic region have multi-hybrid genetic composition, being relevant its inclusion in cancer pharmacogenomics [164, 165] . Figure 5 is an innovative way to visualize and correlate the minor allele frequencies of 43 genes related to the different categories of drugs applied in CRC treatments in 8674 samples from 9 Latin American countries (p < 0.001). This information will make it easier for public health decisionmakers to take decisions regarding CRC treatments. The inclusion of political support can guide the clinical practice in order to decrease the gap of inequalities among the populations that cannot access to private services, especially cancer treatments, which are extremely expensive. For instance, the minor allele (G) of GSTP1 rs1695 can alter GST activity reducing detoxification capacity and leading to increased efficacy of platinum compounds [49, 50] . Thus, the Latin American countries whom best reduce the detoxification capacity and increase the efficacy of platinum compounds are Venezuela, Mexico and Peru due to their populations have a G allele frequency ≥ 0.50. Fig. 4 Biomarker network in CRC made up of driver genes, genes with pathogenic germline mutations, genes with somatic mutations, and druggable enzymes by antitopoisomerase, antimetabolite, platinum derivative, and antiangiogenic drugs. The PPi network with a highest confidence cutoff of 0.9 was created using String Database On the other hand, it is imperative to unify efforts between private companies and governments to increase investment in pharmacogenomics fomenting precision medicine in CRC treatments. The most relevant barriers to implement pharmacogenomics testing in Latin America are the need for clear guidelines for the use of pharmacogenomics, the insufficient awareness of pharmacogenomics among clinicians, the absence of a regulatory institution that facilitates the use of pharmacogenomics tests, and the importance of including the public health scenario that ensures the benefits of precision medicine to the most vulnerable people [166] . By overcoming the previously mentioned barriers, pharmacogenomics will make it possible to improve the efficiency on the use of resources, patient safety, and drug dosage in CRC treatments [167] .
Conclusion
In the era of precision medicine, multisectorial collaborations are important to unify all current knowledge about CRC biology and treatment. There is the need to link sectors not only for funds but also to create a common goal to benefit all socioeconomic groups. In addition, large-scale projects worldwide have studied the multiomics landscape of CRC by implementing the CMS classification and generating new therapeutic targets related to different populations worldwide. Developed countries might incorporate racial/ethnic minority populations in future cancer researches and clinical trials, and developing countries might invest in obtaining a database of genomic profiles of their populations with the overall objective of linking pharmacogenomics in clinical practice and public health policies.
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